Newly discovered bat virus shares the same entry method as Covid-19
Listen to article
A newly discovered bat coronavirus uses the same cell-surface protein to gain entry into human cells as the SARS-CoV-2 virus that causes COVID-19, Chinese researchers have reported.
The virus does not enter human cells as readily as SARS-CoV-2 does, the Chinese researchers reported in the journal Cell, noting some of its limitations.
The scientists said that like SARS-CoV-2, the bat virus HKU5-CoV-2 contains a feature known as the furin cleavage site that helps it to enter cells via the ACE2 receptor protein on cell surfaces.
In lab experiments, HKU5-CoV-2 infected human cells with high ACE2 levels in test tubes and in models of human intestines and airways.
In further experiments, the researchers identified monoclonal antibodies and antiviral drugs that target the bat virus.
Bloomberg, which reported on the study earlier on Friday, said the paper identifying the bat virus had moved shares of COVID vaccine makers. Pfizer (PFE.N) shares closed up 1.5% on Friday, Moderna (MRNA.O) climbed 5.3% and Novavax (NVAX.O) was up about 1% on a down day for the broader market.
Asked about concerns raised by the report of another pandemic resulting from this new virus, Dr. Michael Osterholm, an infectious disease expert at the University of Minnesota, called the reaction to the study "overblown."
He said there is a lot of immunity in the population to similar SARS viruses compared with 2019, which may reduce the pandemic risk.
The study itself noted that the virus has significantly less binding affinity to human ACE2 than SARS-CoV-2, and other suboptimal factors for human adaptation suggest the "risk of emergence in human populations should not be exaggerated."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Recorder
13 hours ago
- Business Recorder
Pakistan's vaccine independence: a national imperative
Pakistan stands at a critical crossroads in public health policy. With seven million births annually and a population growth rate of 2.55%, our nation faces an unprecedented challenge in vaccine security that demands immediate and decisive action. The looming withdrawal of GAVI support by 2031 presents not just a crisis, but an opportunity to transform Pakistan into a self-reliant pharmaceutical powerhouse. The stark reality we face The numbers paint a sobering picture of our current vulnerability. Pakistan's complete dependency on donated and discounted vaccine supplies, supported by GAVI, UNICEF, and WHO to the tune of PKR 26 billion annually, masks a deeper structural weakness. When GAVI's support ends in 2031, the financial burden will balloon to PKR 100 billion annually as nearly four times our current federal health budget of PKR 27 billion. This dependency is not merely financial; it represents a fundamental threat to national health security. This isn't just underdevelopment—it's a systematic surrender of national health autonomy. Today, Pakistan produces virtually no antigens for the Expanded Programme on Immunization (EPI) vaccines domestically. We lack essential seed banks, have minimal university-based vaccine development programs, and operate with regulatory guidelines that are inadequate for sophisticated vaccine manufacturing. Our clinical trial expertise remains severely limited, creating bottlenecks in bringing locally developed vaccines to market. The contrast with global pharmaceutical leaders is stark. While universities worldwide have been the birthplace of revolutionary vaccines-from the Hepatitis B vaccine developed at UC San Francisco to the Oxford-AstraZeneca Covid-19 vaccine-Pakistan's academic institutions remain largely disconnected from commercial vaccine production. Learning from global success stories International experience offers valuable lessons. India transformed itself into the 'pharmacy of the world' through strategic government support for generic manufacturing and robust regulatory frameworks. Singapore built a biomedical hub through integrated research, manufacturing, and regulatory excellence that attracted billions in global pharmaceutical investment. South Korea's government-industry partnerships created world-class biopharmaceutical capabilities. These success stories share common elements: sustained government commitment, strategic investment in infrastructure, regulatory excellence, and comprehensive talent development programs. Most importantly, they demonstrate that with the right approach, developing nations can achieve pharmaceutical self-sufficiency and even become global exporters. The Triple Helix solution The path forward requires unprecedented coordination between government, academia, and industry -what experts call the 'Triple Helix' approach. Each sector must play a distinct yet interconnected role in building national vaccine capacity. Government leadership is essential in creating policy frameworks that incentivize domestic production while providing funding for university research. Strategic assignments to national research institutions like the National Institute of Health, Centre of Excellence in Molecular Biology (CEMB), National Institute for Biotechnology and Genetic Engineering (NIBGE), International Centre for Chemical and Biological sciences (ICCBS), Karachi University, Department of Biotechnology, Dow University of Health Sciences (DUHS), etc., can accelerate vaccine development and establish crucial seed banks. Most critically, the government must develop a comprehensive national health security strategy that positions vaccine self-sufficiency as a matter of national defense. The regulatory transformation cannot be understated. Pakistan's Drug Regulatory Authority must achieve WHO Level 3 qualification and create 'regulatory sandboxes — collaborative environments where university researchers, industry partners, and regulatory experts jointly develop guidelines for the 13 critical EPI vaccine antigens. Fast-track approval pathways and clear regulatory roadmaps will accelerate the journey from laboratory research to commercial production. Formation of sandboxes by bringing together leaders of the University, Regulatory and Industry. Universities must step up as innovation engines. Institutions with BSL-III laboratories should lead development of live attenuated vaccines, while biotechnology departments focus on recombinant vaccine technologies. Specialized vaccine research centers, industry-relevant curricula, and technology transfer offices will bridge the gap between academic discovery and commercial application. State-of-the-art pilot manufacturing facilities will provide proof-of-concept capabilities essential for scaling innovations. Industry brings manufacturing excellence and market expertise to the equation. Private sector partners can transform academic research into GMP-compliant commercial production, establish robust supply chains for raw materials, and navigate complex regulatory approvals. Their distribution networks and market access capabilities will ensure that domestically produced vaccines reach every corner of Pakistan. Leading companies in Pakistan already in the field of Biopharmaceutical manufacturing must be involved in the development process. A realistic implementation roadmap Success requires a phased approach spanning six years. The foundation phase (Years 1-2) must establish policy frameworks and coordination mechanisms while launching capacity-building programmes. Infrastructure development (Years 2-4) involves scaling laboratory manufacturing capabilities, establishing vaccine testing facilities, and launching pilot production programs. The scale-up phase (Years 4-6) transitions to commercial production of EPI vaccines, regulatory approvals, and distribution network establishment. Finally, the optimization phase (Year 6+) expands manufacturing capabilities, develops advanced biologics production, and positions Pakistan as a regional pharmaceutical hub. Financial innovation will be crucial. Blended financing models combining public funding, private investment, and support from institutions like the Islamic Development Bank can mobilise the substantial capital required for drug substance manufacturing facilities. The initial investment may be significant, but the long-term savings and export potential far outweigh the costs. The economic and strategic imperative The benefits extend far beyond health security. A robust domestic vaccine industry could create over 5,000 jobs and reduce import dependency by 50 percent. More importantly, it would establish Pakistan as a regional pharmaceutical hub with significant export potential to neighboring countries and the broader Islamic world. The Covid-19 pandemic demonstrated the critical importance of pharmaceutical self-reliance. Nations with domestic production capabilities could respond rapidly to their populations' needs, while others waited months for external supplies. This lesson cannot be ignored as we face an uncertain global health landscape. The time for action is now Pakistan's demographic dividend — with 65 percent of the population under 30 — represents an unprecedented opportunity to build a knowledge-based pharmaceutical sector. However, this window will not remain open indefinitely. The GAVI deadline of 2031 provides a clear timeline for action, but preparation must begin immediately. The success of this transformation depends on political will, sustained investment, and most importantly, recognition that vaccine self-sufficiency is not a luxury but a national security imperative. Countries that fail to develop domestic pharmaceutical capabilities will remain perpetually vulnerable to supply disruptions, price volatility, and foreign policy pressures. A call to national action The establishment of National and Provincial Coordination Committees bringing together leaders from academia, industry, and regulatory agencies represents the essential first step. This must be followed by a comprehensive assessment of current capabilities, development of a detailed national vaccine strategy, and launch of pilot programmes for immediate impact. Pakistan has the intellectual capital, institutional foundation and market potential to achieve vaccine independence. What we need now is the collective will to transform this potential into reality. The health and prosperity of future generations depend on the decisions we make today. The choice is clear: remain dependent on the goodwill of international donors or invest in building a self-reliant pharmaceutical sector that serves not only Pakistan's needs but positions the nation as a leader in global health innovation. The Triple Helix approach offers a proven pathway to pharmaceutical independence-we must have the courage to take it. Copyright Business Recorder, 2025
Business Recorder
2 days ago
- Business Recorder
Global energy investment set to hit record $3.3 trillion in 2025, IEA says
PARIS: A surge in clean energy spending is expected to drive a record $3.3 trillion (2.89 trillion euros) in global energy investment in 2025, despite economic uncertainty and geopolitical tensions, the International Energy Agency (IEA) said on Thursday. Clean energy technologies, including renewables, nuclear, and energy storage, are set to attract $2.2 trillion in investment, twice the amount expected for fossil fuels, the IEA said in its annual World Energy Investment report. 'The fast-evolving economic and trade picture means that some investors are adopting a wait-and-see approach to new energy project approvals, but in most areas we have yet to see significant implications for existing projects,' IEA Executive Director Fatih Birol said. Solar power is expected to be the biggest beneficiary, with investment forecast to reach $450 billion in 2025, while spending on battery storage is predicted to surge to around $66 billion, the report said. Batteries are seen as a way to mitigate the intermittency of renewable energy projects, by storing power during peak supply and discharging during peak demand, but investments in the technology have lagged behind solar and wind power. In contrast, investment in oil and gas is expected to decline, with upstream oil investment set to fall by 6% in 2025, driven by lower oil prices and demand expectations and the first drop since the Covid crisis in 2020. The IEA also warned that investment in grids of $400 billion per year is lower than spending on generation and electrification, which could pose a risk to electricity security. Low diversity in critical mineral markets could hurt industry, IEA says Grid investments will need to rise to near parity with generation spending by the early 2030s to maintain electricity security, but this is being held back by red tape and tight supply chains for transformers and cables. Spending patterns remain very uneven globally, with many developing economies struggling to mobilise capital for energy infrastructure, while China dominates global clean energy investment at almost one-third of the total.
Express Tribune
3 days ago
- Express Tribune
US CDC COVID vaccine advisor Dr. Lakshmi Panagiotakopoulos resigns: Reuters
Vials labelled "VACCINE Coronavirus COVID-19" and a syringe are seen in front of a displayed U.S. flag in this illustration taken December 11, 2021. Photo:REUTER Listen to article Pediatric infectious disease expert Dr Lakshmi Panagiotakopoulos of the US CDC resigned on Tuesday as co-leader of a working group that advises outside experts on COVID-19 vaccines and is leaving the agency, said two sources familiar with the move. Panagiotakopoulos said in an email to work group colleagues that her decision to step down was based on the belief she is "no longer able to help the most vulnerable members" of the US population. In her role at the Centers for Disease Control and Prevention's working group of the Advisory Committee on Immunization Practices, she co-led the gathering of information on topics for presentation. Her resignation comes one week after Health Secretary Robert F Kennedy Jr, a long-time vaccine skeptic who oversees the CDC, the Food and Drug Administration and the National Institutes of Health, said the COVID vaccine for healthy children and healthy pregnant women had been removed from the CDC's recommended immunization schedule. The move was a departure from the process in which ACIP experts meet and vote on changes to the immunization schedule or recommendations on who should get vaccines before the agency's director made a final call. The committee had not voted on the changes announced by Kennedy and the CDC does not yet have a permanent director. Two days after Kennedy's announcement, the CDC published a vaccine schedule online saying that COVID-19 vaccines remain an option for healthy children aged 6 months to 17 years when parents and doctors agree that it is needed. It had previously recommended updated COVID vaccines for everyone aged six months and older, following the guidance of the panel of outside experts. Two sources said Panagiotakopoulos did not include a specific reason for her departure. Panagiotakopoulos did not return requests for comment. "Unfortunately for me, this is a personal decision," Panagiotakopoulos wrote in an email to members of the working group that was read to Reuters by a source who received it. "My career in public health and vaccinology started with a deep-seated desire to help the most vulnerable members of our population, and that is not something I am able to continue doing in this role." The committee is scheduled to meet on June 25-27 and is expected to deliberate and vote on recommendations for use of COVID-19 vaccines, according to one of the sources who was not authorized to speak publicly.
